Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03233308 · ClinicalTrials.gov registry record · Phase 2
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
A Phase 2 study of Primary Open Angle Glaucoma or Ocular Hypertension, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT03233308 is a Phase 2 study of Primary Open Angle Glaucoma or Ocular Hypertension that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 20 participants, below the 57-participant average among 3 other Primary Open Angle Glaucoma or Ocular Hypertension trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03233308, a Phase 2 study of Primary Open Angle Glaucoma or Ocular Hypertension, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
Conditions Studied
Interventions
- OTHER Placebo Comparator
- DRUG Netarsudil Ophthalmic Solution 0.02%
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Duke Eye Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2018-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03233308
The ClinicalTrials.gov registry entry for NCT03233308 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 57-participant average among 3 other Primary Open Angle Glaucoma or Ocular Hypertension trials with a reported enrollment target (65% lower). The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Open Angle Glaucoma or Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT03233308 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03233308 about?
NCT03233308 is a clinical study titled "Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)". To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
What is the current status of trial NCT03233308?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-10-20. Estimated completion is 2018-04-19.
What conditions does trial NCT03233308 study?
This clinical trial studies the following conditions: Primary Open Angle Glaucoma or Ocular Hypertension.
What interventions are being tested in trial NCT03233308?
The interventions under investigation include: Placebo Comparator (OTHER), Netarsudil Ophthalmic Solution 0.02% (DRUG).
Who is sponsoring clinical trial NCT03233308?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03233308 being conducted?
This trial has 2 study locations across Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Open Angle Glaucoma or Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
RECRUITING
-
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.